This post was originally published on this site
Investing.com – Bellus Health stock (NASDAQ:BLU) surged 64% Monday after the company revealed positive results from a trial of a treatment it is developing against refractory chronic cough.
RCC is a cough lasting more than eight weeks despite appropriate treatment. Around 9 million patients in the U.S. are estimated to be suffering from RCC.
The company expects to meet the Food and Drug Administration between April and June and begin a phase-3 study of the treatment in the second half of the year.
The stock touched a high of $9.39 so far on Monday.
Bellus is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders.
The company reported its third-quarter numbers last month, reporting losses that more than tripled to $23 million. Research and development expenses rose 229%, to $19 million.
Currently, there is no specific therapy approved for RCC and treatment options are limited, according to Bellus. The trial enrolled 249 participants with a baseline awake cough frequency of 25 per hour and more.
